Actasvo 0,5 mg Capsules
PDF Leaflet Revision Date: 18 June 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of Benign Prostatic Hyperplasia (BPH).
Dosage (summary)
1 capsule (0.5 mg) orally once daily.
Onset of Action / Duration
Onset: 1-2 weeks, Duration: 6-8 hours
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; potential risk to male fetus. Unknown if excreted in breast milk.
Key Drug Interactions
- CYP3A4 inhibitors
- Tamsulosin
- Terazosin
Contraindications
- Hypersensitivity to dutasteride
- Women and children
- Severe hepatic impairment
Common side effects
- Impotence
- Altered libido
- Ejaculation disorders
- Breast disorders
Counselling Points
- Avoid contact with leaking capsules
- Report breast changes
- Use condoms if partner is pregnant
Serious warnings
- Risk of high-grade prostate cancer
- Breast neoplasia
- Cardiovascular adverse events
Important Disclaimer
The Actasvo 0,5 mg Capsules professional information leaflet below is the property of Activo Health and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
